Thiazole-valine peptidomimetic (TTT-28) antagonizes multidrug resistance in vitro and in vivo by selectively inhibiting the efflux activity of ABCB1

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Wang, Yi Jun ^a   Patel, Bhargav A ^a   Anreddy, Nagaraju ^a   Zhang, Yun Kai ^a   Zhang, Guan Nan ^a   Alqahtani, Saeed ^b   Singh, Satyakam ^a   Shukla, Suneet ^c   Kaddoumi, Amal ^b   Ambudkar, Suresh V ^c   Talele, Tanaji T ^a   Chen, Zhe Sheng ^a  

^a ST JOHN'S UNIVERSITY   (United States)

^b UNIVERSITY OF LOUISIANA AT MONROE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PEPTIDOMIMETIC AGENT; THIAZOLE DERIVATIVE; VALINE;

ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; CELL SURVIVAL; DRUG EFFECT; HUMAN; METABOLISM; MOUSE; MULTIDRUG RESISTANCE; NEOPLASM; TREATMENT OUTCOME; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE, SUB-FAMILY B, MEMBER 1; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, MULTIPLE; HETEROGRAFTS; HUMANS; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS; PACLITAXEL; PEPTIDOMIMETICS; THIAZOLES; TREATMENT OUTCOME; VALINE;

EID: 85012041098     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep42106     Document Type: Article

References (36)

1. Siegel, R., DeSantis, C. & Jemal, A. Colorectal cancer statistics, 2014. CA: a cancer journal for clinicians 64, 104-117 (2014).
2. Deeley, R. G., Westlake, C. & Cole, S. P. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol. Rev. 86, 849-899 (2006).
3. Gottesman, M. M., Fojo, T. & Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer. 2, 48-58 (2002).
4. Mao, Q. Role of the breast cancer resistance protein (ABCG2) in drug transport. The AAPS journal 7, E118-E133 (2005).
5. Zahreddine, H. & Borden, K. Mechanisms and insights into drug resistance in cancer. Frontiers in pharmacology 4, 28 (2013).
6. Dean, M. & Annilo, T. Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. Annu. Rev. Genomics Hum. Genet. 6, 123-142 (2005).
7. Dlugosz, A. & Janecka, A. ABC Transporters in the Development of Multidrug Resistance in Cancer Therapy. Curr. Pharm. Des. 22, 4705-4716 (2016).
8. Sharom, F. J. The P-glycoprotein multidrug transporter. Essays Biochem. 50, 161-178 (2011).
9. Sarkadi, B., Homolya, L., Szakacs, G. & Varadi, A. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol. Rev. 86, 1179-1236 (2006).
10. Matsuo, K. et al. Multidrug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer. Am. J. Clin. Oncol. 34, 488-493 (2011).
11. Eechoute, K. et al. Drug transporters and imatinib treatment: implications for clinical practice. Clin. Cancer Res. 17, 406-415 (2011).
12. Gao, B. et al. Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer. Sci. Rep. 4, 4669 (2014).
13. Han, J. Y. et al. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 110, 138-147 (2007).
14. Wang, Y., Zhang, Y., Kathawala, R. J. & Chen, Z. Repositioning of tyrosine kinase inhibitors as antagonists of ATP-binding cassette transporters in anticancer drug resistance. Cancers 6, 1925-1952 (2014).
15. Singh, S. et al. Design and synthesis of human ABCB1 (P-glycoprotein) inhibitors by peptide coupling of diverse chemical scaffolds on carboxyl and amino termini of (S)-valine-derived thiazole amino acid. J. Med. Chem. 57, 4058-4072 (2014).
16. Calcagno, A. M. & Ambudkar, S. V. Molecular mechanisms of drug resistance in single-step and multi-step drug-selected cancer cells. Methods Mol. Biol. 596, 77-93 (2010).
17. Rabindran, S. K., Ross, D. D., Doyle, L. A., Yang, W. & Greenberger, L. M. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res. 60, 47-50 (2000).
18. Vanhoefer, U. et al. PAK-104P, a pyridine analogue, reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein. Clin. Cancer Res. 2, 369-377 (1996).
19. Zhou, Y. et al. Cepharanthine is a potent reversal agent for MRP7 (ABCC10)-mediated multidrug resistance. Biochem. Pharmacol. 77, 993-1001 (2009).
20. Loo, T. W. & Clarke, D. M. Mapping the Binding Site of the Inhibitor Tariquidar That Stabilizes the First Transmembrane Domain of P-glycoprotein. J. Biol. Chem. 290, 29389-29401 (2015).
21. Nemzek, J., Bolgos, G., Williams, B. & Remick, D. Differences in normal values for murine white blood cell counts and other hematological parameters based on sampling site. Inflammation Res. 50, 523-527 (2001).
22. Missov, E., Calzolari, C. & Pau, B. Circulating cardiac troponin I in severe congestive heart failure. Circulation 96, 2953-2958 (1997).
23. Wang, T. J. Significance of circulating troponins in heart failure: if these walls could talk. Circulation 116, 1217-1220 (2007).
24. Patel, A. et al. PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells. Cancer Chemother. Pharmacol. 72, 189-199 (2013).
25. Robert, J. & Jarry, C. Multidrug resistance reversal agents. J. Med. Chem. 46, 4805-4817 (2003).
26. Shukla, S., Ohnuma, S. & Ambudkar, S. V. Improving cancer chemotherapy with modulators of ABC drug transporters. Curr. Drug Targets 12, 621-630 (2011).
27. Wang, Y. et al. Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1. Biochem. Pharmacol. 90, 367-378 (2014).
28. Zhang, H. et al. Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance. Int. J. Biochem. Cell Biol. 51, 111-119 (2014).
29. Zhang, Y. et al. Esters of the marine-derived triterpene sipholenol A reverse P-GP-mediated drug resistance. Marine drugs 13, 2267-2286 (2015).
30. Guo, H. Q. et al. beta-Elemene, a compound derived from Rhizoma zedoariae, reverses multidrug resistance mediated by the ABCB1 transporter. Oncol. Rep. 31, 858-866 (2014).
31. Zhang, H. et al. AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance. Cancer Lett. 350, 61-68 (2014).
32. Ambudkar, S. V. Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells. Methods Enzymol. 292, 504-514 (1998).
33. Wang, Y. J. et al. Tea nanoparticle, a safe and biocompatible nanocarrier, greatly potentiates the anticancer activity of doxorubicin. Oncotarget 7, 5877-5891 (2016).
34. Anreddy, N. et al. A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDR in vitro and in vivo. Oncotarget 6, 39276-39291 (2015).
35. Wang, D. S. et al. Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2. Oncotarget 5, 4529-4542 (2014).
36. Kathawala, R. J. et al. The small molecule tyrosine kinase inhibitor NVP-BHG712 antagonizes ABCC10-mediated paclitaxel resistance: a preclinical and pharmacokinetic study. Oncotarget 6, 510-521 (2015).